McKeigue, P. M.Porter, D.Hollick, R. J.Ralston, S. H.McAllister, D. A.Colhoun, H. M.2023-09-262023-09-262023McKeigue, P M, Porter, D, Hollick, R J, Ralston, S H, McAllister, D A & Colhoun, H M 2023, 'Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland', Scandinavian Journal of Rheumatology, vol. 52, no. 4, pp. 412-417. https://doi.org/10.1080/03009742.2022.20633760300-9742ORCID: /0000-0001-6558-7189/work/143412784https://hdl.handle.net/2164/21761Funding Information: No specific funding was received for this study. We thank Jen Bishop, Ciara Gribben, and David Caldwell for undertaking the linkage analysis in Public Health Scotland, and staff from the rheumatology service in the contributing centres for preparing the list of patients receiving these treatments.6579583engR Medicine (General)RheumatologyImmunology and AllergyImmunologySupplementary DataGithubR1Journal article10.1080/03009742.2022.2063376https://www.scopus.com/pages/publications/85130276726